Alpelisib (BYL719) Mechanism of Action: PI3Kα Inhibition in Breast Cancer Cell Research

Alpelisib (BYL719) MOA:Targeting PI3Kα/PI3K-AKT Pathway for Breast Cancer

🎯 check Alpelisib (BYL719) product page

Alpelisib (BYL719) is a potent, selective PI3Kα inhibitor. It affects PI3K/AKT/mTOR signaling by inhibiting PI3K activity and inducing p110α degradation, effectively suppressing cancer cell proliferation and inducing apoptosis.

Primary Applications and Mechanism of Action